What is Perosphere?
Perosphere operates within the specialty pharmaceutical sector, focusing on identifying market opportunities where its advanced drug delivery technology can enhance existing drugs or create new medical uses. The company also selectively develops new chemical entities and therapeutics, particularly "rescue" drugs. Its lead candidate, PER977, is a clinical-stage anticoagulant reversal agent designed for direct factor Xa- and IIa-inhibitors, representing a critical advancement in patient safety for anticoagulant therapies.
How much funding has Perosphere raised?
Perosphere has raised a total of $8.9M across 4 funding rounds:
Series A
$1M
Debt
$1.5M
Series B
$6.2M
Debt
$150K
Series A (2011): $1M, investors not publicly disclosed
Debt (2014): $1.5M led by Connecticut Innovations
Series B (2015): $6.2M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in Perosphere
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
What's next for Perosphere?
The recent major strategic investment signals Perosphere's transition into a scaling phase, likely aimed at advancing PER977 through late-stage clinical trials and preparing for potential commercialization. This capital infusion will be crucial for expanding its research and development capabilities, navigating regulatory pathways, and potentially forging strategic partnerships to maximize the reach of its innovative drug delivery platform and rescue drug candidates. The company's focus on enhancing existing treatments and developing critical rescue medications positions it to address significant unmet needs in patient care.
See full Perosphere company page
